A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7 <ul> <li>Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837</li> </ul> II KP Vaccinate Trial <ul> <li>KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208</li> <li>IAMI trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042</li> <li>Increasing Flu Vaccinations in Patients With Chronic Disease https://jamanetwork.com/journals/jama/fullarticle/2824956</li> <li>MI FREEE Trial https://www.nejm.org/doi/full/10.1056/NEJMsa1107913</li> </ul> III Hi PRO Trial <ul> <li>Apixaban for Extended Treatment of VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2509426</li> <li>Recurrent VTE in Patients with Provoked VTE https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226140</li> </ul> IV Oral GLP-1 Agonists <ul> <li>ATTAIN 1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511774</li> </ul> You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Sep 26 2025 This Week in Cardiology

This Week in Cardiology

AI Chapters

AI Insights

Reviews